MacroGenics, Inc. (MGNX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MGNX Revenue Growth
Revenue Breakdown (FY 2025)
MGNX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
MGNX Revenue Analysis (2014–2025)
As of May 6, 2026, MacroGenics, Inc. (MGNX) generated trailing twelve-month (TTM) revenue of $149.5 million, reflecting explosive growth of +132.5% year-over-year. The most recent quarter (Q4 2025) recorded $41.2 million in revenue, down 43.4% sequentially.
Looking at the longer-term picture, MGNX's 5-year compound annual growth rate (CAGR) stands at +8.9%, indicating steady revenue expansion. The company achieved its highest annual revenue of $155.5 million in 2017.
Revenue diversification analysis shows MGNX's business is primarily driven by Revenue From Collaborative Agreements (62%), and Contract Manufacturing (38%). With over half of revenue concentrated in Revenue From Collaborative Agreements, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), FATE (-51.2% YoY), and AGEN (+10.4% YoY), MGNX has outperformed the peer group in terms of revenue growth. Compare MGNX vs RCUS →
MGNX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MGNXCurrent | $150M | +132.5% | +8.9% | -48.7% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
MGNX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $149.5M | +0.8% | $0 | - | $-72,841,000 | -48.7% |
| 2024 | $148.3M | +159.4% | $136.0M | 91.7% | $-110,578,000 | -74.5% |
| 2023 | $57.2M | -61.9% | $49.0M | 85.6% | $-168,244,000 | -294.2% |
| 2022 | $150.0M | +98.3% | $142.6M | 95.1% | $-121,418,000 | -80.9% |
| 2021 | $75.6M | -22.6% | $73.0M | 96.5% | $-202,795,000 | -268.1% |
| 2020 | $97.8M | +57.6% | $97.8M | 100.0% | $-131,060,000 | -134.1% |
| 2019 | $62.0M | +3.2% | $62.0M | 100.0% | $-177,185,000 | -285.7% |
| 2018 | $60.1M | -61.3% | $60.1M | 100.0% | $-171,206,000 | -284.8% |
| 2017 | $155.5M | +79.6% | $155.5M | 100.0% | $-22,143,000 | -14.2% |
| 2016 | $86.6M | -14.2% | $86.6M | 100.0% | $-60,042,000 | -69.3% |
See MGNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MGNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MGNX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMGNX — Frequently Asked Questions
Quick answers to the most common questions about buying MGNX stock.
Is MGNX's revenue growth accelerating or slowing?
MGNX revenue is accelerating at +132.5% year-over-year, exceeding the 5-year CAGR of +8.9%. TTM revenue reached $150M. Growth momentum has increased versus prior periods.
What is MGNX's long-term revenue growth rate?
MacroGenics, Inc.'s 5-year revenue CAGR of +8.9% reflects the sustained expansion pattern. Current YoY growth of +132.5% is above this long-term average.
How is MGNX's revenue distributed by segment?
MGNX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.